The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25-30% of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70% of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms -such as TGFa production -possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGFa expression. Moreover, by in vitro expression of exogenous TGFa in breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGFa-related mechanism of escape to HER2 downregulation.
Introduction
The HER2/Neu gene, which encodes a tyrosine kinase receptor with unknown ligand, is amplified and/or overexpressed in 25-30% of human breast cancers. HER2 belongs to the EGFR receptor family. Its activation follows heterodimerization with a member of the EGFR family and triggers important biological effects such as proliferation, migration and differentiation. Immunohistochemistry (IHC), using a semiquantitative system, shows that HER2 is overexpressed (IHC 2 þ and 3 þ ) in approximately 20-25% of breast cancers. FISH (fluorescent in situ hybridization) detects HER2 gene amplification in 80% of IHC 3 þ tumors and in about 20% of IHC 2 þ tumors (Tubbs et al., 2001) .
Since HER2 overexpression is associated with poor prognosis in breast cancers, the use of the humanized monoclonal antibody Trastuzumab, selectively directed against the product of this protooncogene, has generated enthusiasm for the treatment of HER2 overexpressing tumors (Slamon et al., 2001) .
Pilot clinical studies of Trastuzumab monotherapy showed that gene amplification detected by FISH predicts response to Trastuzumab better than IHC. However, the same studies showed that, in the best scenario, response rates range between 15 and 26% (Cobleigh et al., 1999; Vogel et al., 2002) . Considering the overall population of metastatic breast cancer patients, we might thus estimate that approximately 3-5% of them will benefit from this treatment. Moreover, clinical studies have shown that a tumor response is almost invariably followed by progression (Cobleigh et al., 1999; Vogel et al., 2002) .
Clarifying the mechanisms of resistance to Trastuzumab, primary or secondary, is therefore necessary to increase the therapeutic efficacy.
No definite data are available on the mechanisms of action of Trastuzumab in HER2 overexpressing cancer cells; however, it is believed that its action is in part indirect, due to activation of an ADCC immune response and mainly direct, through induction of HER2 downregulation and subsequent degradation (Cooley et al., 1999; Leyland-Jones, 2002; zum Bu¨schenfelde et al., 2002) .
Cbl protein Levkowitz et al., 2000) , an E3 ubiquitin ligase that promotes ubiquitinylation and degradation of activated receptors such as EGFR, HGFR, PDGFR and CSF-1R (Dikic and Giordano, 2003) , plays a critical role in antibody-induced HER2 downregulation. Antibody stimulation induces receptor activation and tyrosine phosphorylation. Phosphorylation of tyrosine 1112 of HER2 allows interaction of the receptor with the tyrosine-kinase-binding (TKB) domain of Cbl , and thus its recruitment to the receptor; upon binding, Cbl catalyses the transfer of ubiquitin molecules to HER2 through its E3 ubiquitin ligase activity. Ubiquitinylated receptor-Cbl complexes are endocytosed by clathrin-coated pits; internalized vesicles are rapidly uncoated, fuse into early endosomes and move to lysosomes where the receptor is destroyed. On the contrary, it has been shown that in the absence of such antibodies, phosphorylated HER2 only weakly associates with Cbl and it is thus resistant to Cbl-induced downregulation (Muthuswamy et al., 1999) . Moreover, HER2 heterodimerization with other members of the EGFR family prevents HER2/Cbl association and avoids the lysosomal fate, favoring recycling (Levkowitz et al., 1995; Graus-Porta et al., 1997; Lenferink et al., 1998; Muthuswamy et al., 1999; Wiley and Burke, 2001) and this accounts for HER2 heterodimers enhanced signaling potency.
Members of the EGFR family can interact with several ligands, endowed with different properties. It has been established that EGF and TGFa differ in their ability to induce EGFR processing (Ebner and Derynck, 1991) . EGF is a more acidic molecule than TGFa and remains bound to EGFR upon internalization, during acidification of the endocytic vesicle, finally resulting in lysosomal degradation of both ligand and receptor. In contrast, TGFa rapidly dissociates from the receptor upon internalization, leading to EGFR recycling to the cell surface (Alwan et al., 2003) . Autocrine secretion of TGFa by tumor cells can thus result in prolonged stimulation of EGFR and of the heterodimerized members of the same family.
As very little is known about the mechanisms underlying the development of resistance to Trastuzumab in HER2 overexpressing breast tumors, we were interested in verifying if this was due to impairment of the machinery responsible for receptor endocytosis and degradation, or to acquisition of properties leading to the overcoming of receptor degradation. We thus investigated the molecular mechanisms responsible for HER2 downregulation induced by the monoclonal antibody Trastuzumab. Here we show that reduced HER2 downregulation is not due to mutations in either HER2 or Cbl sequences involved in the interaction of the two proteins. However, we show that metastatic cells examined after Trastuzumab treatment acquire the ability to express TGFa. Furthermore, we show that in cells transfected with TGFa cDNA, Trastuzumab is able to bind HER2 with the same efficiency as in parental cells, but its ability to negatively control cell growth is severely impaired. Finally, we show experimental evidences suggesting that these events are related to a reduced rate of HER2 internalization and degradation.
Results

Mutational analysis of the HER2 and Cbl domains involved in receptor downregulation
It has been shown that antibody-induced downregulation of the tyrosine kinase receptor HER2 requires phosphorylation of a critical tyrosine (Y1112) in the intracellular portion of this receptor . This phosphorylated tyrosine mediates the interaction with the Cbl ubiquitin ligase that, in turn, ubiquitinylates HER2 and activates the machinery for its endocytosis and downregulation. In experimental conditions, either mutation of tyrosine 1112 or abrogation of the Cbl ligase acitivity results in decreased HER2 downregulation . We thus analysed genomic DNAs extracted from 63 patients (58 primary tumors and five liver metastases, Tables 1 and 2 ) with disease at different stages and we searched for mutations either in the region close to Y1112 of HER2 or in the RING-finger and linker regions of Cbl (previously shown to be critical for Cbl ligase activity). Although we carefully sequenced both the strands of the obtained DNAs, we were unable to find mutations in the examined regions of these two genes (data not shown).
TGFa is a potential resistance factor to Trastuzumab treatment
It has been shown that HER2 hetero-dimerization with other members of the EGFR family prevents HER2/Cbl association and avoids the lysosomal fate, favoring recycling (Graus-Porta et al., 1997; Levkowitz et al., 1995; Lenferink et al., 1998; Muthuswamy et al., 1999; Wiley and Burke, 2001) . Thus, in the absence of anti-HER2 antibodies, phosphorylated HER2 only weakly associates with Cbl and it is resistant to Cbl-induced We thus analysed the expression of TGFa in biopsies derived from the same metastasis before and upon Trastuzumab progression. We could perform this analysis in two patients where the same neoplastic tissue (a liver metastasis in patient 1, and a controlateral tumor re-grown during Trastuzumab treatment in patient 2) was available before and after treatment. In a third patient we could analyse TGFa expression on the primary tumor and on supraclavear metastasis grown during Trastuzumab treatment. As shown in Figure 1 , we observed a strong increase of TGFa expression in the neoplastic tissue biopsy upon Trastuzumab progression.
TGFa renders breast cancer cells partially resistant to Trastuzumab treatment
Preliminary experiments performed in SKBR3 cells showed that Trastuzumab treatment was able to decrease cell growth ( Figure 2a ). To evaluate if TGFa expression could impair cell responsiveness to Trastuzumab, we produced a polyclonal population of SKBR3 cells, SKBR3(TGFa), transfected with an expression vector containing the TGFa cDNA ( Figure 1b ). When examined, SKBR3(TGFa) cells displayed a partial resistance to the inhibitory effect induced by Trastuzumab ( Figure 2a ). This inhibition was mainly due to reduced proliferation rather than to increased apoptosis (data not shown).
We then analysed the level of HER2 upon Trastuzumab treatment and we observed that Trastuzumabinduced HER2 downregulation was significantly impaired in SKBR3(TGFa) cells, in comparison to parental cells (Figure 2b ) even if the ability of the antibody to bind HER2 was not affected by the expression of TGFa (Figure 2c ).
Moreover, when we evaluated the ability of HER2 to interact with the Cbl ubiquitin ligase, we observed that in TGFa-expressing cells the association between HER2 and Cbl was severely impaired, both in basal conditions and upon Trastuzumab treatment ( Figure 2d ).
HER2 internalization and sorting is delayed in the presence of TGFa
To define whether the decreased downregulation of HER2 in TGFa expressing cells was associated with changes in the kinetic of receptor endocytosis and/or degradation, we performed an immuno-gold endocytic assay (Table 3 ). SKBR3 and SKBR3(TGFa) cells were incubated in the presence of Trastuzumab and protein A-gold at 41C. This approach allowed the immuno-gold labeling of HER2 present on the cell surface, in the absence of internalization. Cells were then transferred at 371C, to allow the Trastuzumab-dependent internalization of the HER2/Trastuzumab/ProteinA-gold complex, and were chased for 2, 20, 45 and 120 min before fixation. By morphometry, we first evaluated the percent of gold associated to the plasma membrane at each time point versus the total gold counted in each cell profile (Table 3) . The results revealed a dramatic delay in HER2 internalization in SKBR3(TGFa), when compared to SKBR3 cells (Table 3 ). In particular, after 45 min of incubation at 371C, the percent of gold particles associated to plasma membrane in SKBR3(TGFa) was about double than in control SKBR3 cell, namely 54 versus 22% (Table 3) . We then calculated the relative distribution among the endocytic pathway of the gold particles found associated to intracellular compartments at the same time points (Table 4 ). In particular, we considered plasma membrane invaginations (i.e. caveolae, clathrin coated pits, tubular invaginations), early endosomes, late endosomes and lysosomes. We could not detect any gold in caveolae, and only negligible amount in clathrin coated pits (Table 4) , suggesting an internalization mechanism independent from these two pathways for the Trastuzumab-dependent endocytosis (Nichols and LippincottSchwartz, 2001; Johannes and Lamaze, 2002; Conner and Schmid, 2003) . Accordingly, after 2 min at 371C we found that all of the gold not associated to plasma membrane was concentrated in characteristic tubular invaginations (Table 4 , Figure 3 ), in both SKBR3(TGFa) and SKBR3 cells. However, while all of the intracellular gold particles (i.e. 55 and 30% of total gold in SKBR3 and SKBR3(TGFa) cells, respectively) were found associated with early endosomes after 20 min of chase in SKBR3 (Table 4 , Figure 3 ), more Figure 3 ). These results suggested that the reduced rate of Trastuzumab-dependent HER2 internalization in TGFa expressing cells could be due to reduced efficiency of recruitment in the tubular invaginations. The transit time from tubular invaginations to early endosomes appeared to be similar in the two cell types used. In particular, after 45 min of chase, both SKBR3 and SKBR3(TGFa) cells displayed a similar relative gold distribution in early endosomes and late endosomes (Table 4, Figure 3) . After 2 h of chase at 371C, a consistent amount of the gold particles were found associated to lysosomes (Table 4 , Figure 3) . However, the interpretation of this latter result is biased by the possibility that, given the low pH in late endosomes/ lysosome compartments, Trastuzumab, Protein A-gold and HER2 may have uncoupled from each other.
Discussion
Overexpression of HER2, a member of the EGF receptor family, is found in about 20% of breast cancer patients and it is associated with poor prognosis. Trastuzumab treatment of metastatic breast tumors (434) 54 (402) 13 (184) Data are expressed as the percent of the total gold particles (n) counted on a total of 20 random cell profiles per sample. The cell profiles analysed were obtained from two separate ultrathin sections (10 cell profiles each), cut at 100 mm distance one from the other. The results are representative of two separate experiments Data are expressed as the percent of the total gold particles counted (n ¼ ), found associated to each single compartment. The results shown here are obtained from the experiment presented in Table 3 , and are representative of two separate experiments TGFa and Trastuzumab resistance G Valabrega et al expressing high levels of HER2 has shown to induce benefits in patients in terms of response and survival. However, two major problems reduce the potential benefits of this treatment, that is, only a small percentage of candidate patients are responsive to treatment, and most of them acquire resistance to Trastuzumab during therapy. The aim of our work was to investigate the mechanisms responsible for this lack of response.
The molecular mechanisms of action of Trastuzumab are only partially understood. Previous work has shown that Trastuzumab inhibits HER2 constitutive shedding that gives origin to an active form of HER2 (p95) endowed with a high oncogenic potential (Molina et al., 2001) . More recent data provide evidence that Trastuzumab could act also by inhibiting the PI3K-AKT pathway, as a consequence of PTEN activation. In fact, following Trastuzumab treatment, the HER2/Src TGFa and Trastuzumab resistance G Valabrega et al association is impaired. This leads to reduced activation of Src, resulting in decreased phosphorylation of PTEN, a well-known PI3K inhibitor; in this condition PTEN is more active and can impair the antiapoptotic activity of PI3K (Nagata et al., 2004) . It is also worth of note that Klapper et al. (2000) have shown that a monoclonal antibody similar to Trastuzumab (L26mAb), directed against the extracellular portion of HER2, induces HER2 activation and interaction with the Cbl ubiquitin ligase, which in turn ubiquitinylates the receptor and promotes its degradation. Furthermore, experimental work has shown that impairment of HER2/Cbl binding leads to defective HER2 degradation.
In the last few years, a big effort has been done in the mutational analysis of genes encoding for tyrosine kinases involved in cancer, in order to predict response to targeted therapies. In patients affected by chronic myelogenous leukemia, point mutations in the ATP binding site of the BCR-ABL, leading to an aminoacidic switch, are responsible for the development of resistance to the BCR-ABL targeting drug STI-571 (Gleevec) (Shah and Sawyers, 2003) . On the other hand, in human non-small-cell lung carcinomas (NSCLC), point mutations or small deletions in the tyrosine kinase domain of the EGFR result in an increased affinity of the specific reversible TK inhibitor gefitinib (Iressa) for the receptor (Lynch et al., 2004; Paez et al., 2004) . As a consequence, lung cancer patients harboring a mutated EGFR are much more sensitive to the therapy with Gefitinib. Following these premises, we wanted to explore the possibility that lack of response to Trastuzumab could be due to mutation preventing the interaction between HER2 and the cellular machinery responsible for its downregulation. We have therefore sequenced genomic DNAs, derived from human breast cancers, analyzing the regions of HER2 and Cbl responsible for their interaction, but we did not find mutations. We thus conclude that a defect in the interaction between HER2 and Cbl, due to sequence mutations, is probably not a major factor in inducing resistance to Trastuzumab treatment. Downregulation of receptors of the EGFR family is a complex biological process that is still not completely understood. Members of this family can form homo-or heterodimers that undergo different intracellular fates (Yarden and Sliwkowski, 2001) . Many studies have shown that HER2 is the 'preferred dimerization partner' inside this family and that EGFR/HER2 heterodimers are endowed with an increased signaling ability compared to EGFR/EGFR homo-dimers. This is, at least in part, due to a decreased ability of the heterodimers to undergo endocytosis and degradation. We thus wondered if one of the mechanisms leading to resistance to Trastuzumab treatment could be related to the ability of cancer cells to produce ligands able to activate EGFR family members and to induce activation of receptor heterodimers. Up to now, eight ligands have been shown to be responsible for activation of the different receptors of this family. Among them, TGFa is frequently 'de novo' expressed by cancer cells and it has been shown to cooperate with HER2 in a bitransgenic mice model of coexpression of TGFa and HER2 (Muller et al., 1996) . Moreover, since TGFa induces EGFR recycling to the cell surface better than degradation, autocrine secretion of TGFa by tumor cells can result in prolonged stimulation of EGFR and of the heterodimerized members of the same family (Alwan et al., 2003) . We thus evaluated if breast cancers becoming resistant to Trastuzumab had acquired the ability to produce TGFa. Although we examined a low number of cases, in those available we found that neoplastic cells, analysed before and after treatment, displayed a strong increase of TGFa production upon progression under Trastuzumab. It is unlikely that the antibody per se induces this increased expression, since it has been recently shown that TGFa expression is not significantly induced upon treatment with Trastuzumab (Kumar-Sinha et al., 2003) . After verifying that TGFa production did not interfere with the ability of Trastuzumab to bind HER2, indeed, we observed that in TGFa expressing cells, Trastuzumabinduced growth inhibition was severely impaired and HER2 degradation strongly decreased. We hypothesize that the autocrine production of this growth factor results in active HER2/EGFR heterodimers, uncoupling HER2 from the Cbl ubiquitin ligase and leading to a less efficient progression along the endocytic pathway. Our ultrastructural and morphometric data further support this content. In particular, they highlight a delay in the Trastuzumab-induced HER2 internalization process in the presence of TGFa. The reduced rate of internalization was associated to a reduced rate of HER2 recruitment into tubular invaginations stemming from the plasma membrane. These data strongly suggest that the reduced rate of degradation may rely mainly on an impaired mechanism of internalization. It is worth of note that we have identified neither clathrin coated pits nor caveolae associated to Trastuzumab labeled HER2, suggesting that the tubular invaginations, found to be heavily labeled in both control and TGFa expressing cells, may represent a novel mechanism of clathrin-and caveolae-independent receptor endocytosis (Nichols and Lippincott-Schwartz, 2001; Johannes and Lamaze, 2002; Conner and Schmid, 2003) . However, further studies are needed to address this hypothesis.
Therefore, although it is conceivable that TGFa production can per se confer a growth advantage to expressing cells, it is likely that in naturally occurring tumors, the acquired ability of cancer cells to produce this ligand, renders the cell less sensitive to the inhibitory effect of Trastuzumab. Moreover, our data may help to provide a molecular explanation to the results obtained in vitro and in vivo where Trastuzumab has been shown to cooperate with small tyrosine kinase inhibitors (Normanno et al., 2002) . Inhibition of active heterodimers could in fact lead to an increased HER2 amount available for interaction with Trastuzumab. Therefore, the present study provides evidence that Trastuzumab resistance is unlikely to be due to an intrinsic defect of the machinery responsible for HER2 degradation, but is probably associated with impaired HER2 downregulation due to uncoupling from Cbl, leading to a different and impaired pattern of endocytosis. Production of TGFa may be involved for the uncoupling mechanism and for the resulting altered trafficking of the receptor and could thus account for primary or acquired resistance to Trastuzumab.
Materials and methods
Patients
We examined a total of 63 tumor specimens (38 IHC 2 þ and 25 IHC 3 þ ). In total, 58 were primary breast cancers from patients who underwent curative surgery, whereas five specimens were collected from metastatic breast cancer patients enrolled in an institutional phase II trial of Trastuzumab docetaxel. In patients displaying tumor response after six cycles, weekly Trastuzumab was administered until tumor progression. For two patients, tumor samples, both before treatment and during Trastuzumab maintenance at the time of progression, were available. Both patients showed a regrowth of a metastasis that initially responded after 18 and 55 weeks of Trastuzumab maintenance (Tables 1 and 2 ). In a third patient we measured TGFa expression on the primary tumor and on a supraclavear metastasis developed after progression during Trastuzumab. The metastasis developed after 85 weeks of Trastuzumab treatment. All patients gave written informed consent for the use of paraffin-embedded tissues for DNA extraction and analysis.
Cells, reagents, plasmids SKBR3 were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% glutamine, penicillin-streptomycin fungizon (PFS). Cells were grown at 371C, in a CO 2 5% atmosphere.
The following antibodies were used for Western blot and IP analyses: anti-Neu c-18, anti-Cbl c-15, anti-b actin (Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
The following antibodies were used for flow cytometry: goat-anti-human IgG PE (Southernbiotech Birmingham, AL, USA), anti-HER2 PE (BD biosciences, Franklin Lakes, NJ, USA). Trastuzumab experiments were performed using a 10 mg/ml concentration in 5% serum.
The Cbl cDNA was cloned in the p156RRLsin-PPThCMVMCSpre lentiviral vector kindly provided by L Naldini.
DNA preparation and analysis
DNA sequencing analysis was performed on primary tumors in 58 patients and on tissues derived from liver metastases in five patients. FISH analysis was available only for the tissues from liver metastases (four patients were FISHÀ, IHC 2 þ and one patient was FISH þ , IHC 3 þ ). The pathologist, to guarantee the prevalence of neoplastic tissue on normal stroma, analysed all specimens used for sequencing.
Genomic DNAs from paraffin embedded breast cancer tissues were obtained by paraffin dissolution with xylene, followed by ethanol 100% washes, addition of lysis buffer (100 mM Tris-HCL pH 8.5, 5 mM EDTA pH 8, 2% SDS, 200 mM NaCl, 100 mg/ml proteinase K), isopropanol precipitation and final wash with 70% ethanol. Sequencing reactions were performed by PCR in order to identify mutations in the HER2 Tyrosine 1112 and in the LINKER and RING regions of Cbl.
All PCR reactions were conducted in a 50 ml final volume:
Sterile water: 33.5 ml. Buffer 10 Â þ MgCl 2 25/mM: 5 ml (Dynazime). DNTPs 2.5 mM: 5/ml. Primer sense: 30 pm in 1 ml. Primer antisense: 30 pm in 1 ml. Taq polimerase Dynazime (2 U/ml): 0.5 ml. Genomic DNA: 100 ng in 4 ml.
In total, 50 ng of each PCR products were sequenced using the DNA sequencing Kit Big Dye Terminator Cycle Sequencing v2.0 Ready Reaction ABI PRISM (PE Biosystems), precipitated and washed with 75% isopropanol and run on a PE ABI PRISM 310 Genetic analyser.
For Cbl sequencing we used primers located in the intronic sequences flanking the exons containing the LINKER region and RING region. Thermal profile for amplification: 35 cycles starting with denaturation 30 s at 941C, followed by 30 s of annealing at 551C, 40 s of extension at 721C.
Immunohistochemistry
IHC for HER2 was performed using the Herceptest (DAKO, Denmark). IHC for TGFa was performed on sections from the two patients cited above. The SKBR3 human breast cancer cell line transfected with TGFa was used as positive control.
Tissue sections of 4 mm thickness were prepared, mounted on silanized slides, following formalin-fixed, paraffin-embedded sections were deparaffinized, immersed in Antigen Retrieval Citra solution (BioGenex, San Ramon, CA, USA) and exposed to microwave oven (700, two cycles 5 0 each). The anti-human TGFa antibody (R&D Systems, Inc., Minneapolis, MN, USA) working dilution was 15 mg/ml in TBS. The sections were incubated with anti-TGFa at RT for 1 h. The detection system kit used was DAKO Universal LSAB/DAB (DAKO, Denmark).
TGFa expression was evaluated as positive when there was cytoplasmic immunostaining and the intensity of staining was scored as follows: strong ( þ þ þ ), moderate ( þ þ ), weak ( þ ).
Transfection, Western blotting, growth curves SKBR3 Cells were transfected with 5 mg of each plasmid and cultured for 48 h.
For immunoprecipitation experiments, cells were lysed with EB buffer (20 mM Tris HCl, pH 7.4, 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% Triton X-100) in the presence of protease inhibitors and 1 mM Na-orthovanadate. After immunoprecipitation with the appropriate antibodies, high stringency washes were performed (EB plus 1 M LiCl).
Western blots were performed according to standard methods. Final detection was carried out with ECL system (Amersham, Buckingamshire, UK).
Growth curves were carried out in quadruplicate. In total, 1500 cells were plated on 0.32 square cm. Cells were fixed with 11% glutaraldehyde, stained with crystal violet and the absorbance was read using a standard colorimetric system.
Electron microscopy
SKBR3 and SKBR3(TGFa) cells were incubated with Trastuzumab (1 : 1000) in serum-free RPMI 1640, 45 min at 41C, washed, and incubated with ProteinA-gold (10 nm) in PBS, 30 min at 41C. The cells were then washed and placed for 2, 20, 45 and 120 min at 371C, in prewarmed standard culture medium. At each time point, the cells were processed for EM as described (Tacchetti et al., 1987) . Briefly, cells were fixed with 2.5% glutharaldehyde in 0.1 M cacodylate buffer pH 7.3, postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer pH 7.3, dehydrated in ethanol and processed for epon embedding (Polybed 812, Polysciences, Inc.). Morphometry was performed on two series of 10 random cell profiles, photographed at 12 000 Â , for each experiment. Each series was obtained from sections cut at 100 mm thickness from each other. Two separate experiments were analysed for each condition. Label density was obtained as described (Rabouille, 1999) .
